Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRDM2
REST API REST API
Homo sapiens
PRDM2 is differentially expressed in 352 experiments: 157 organism parts: cerebellum, liver, ... (155 more);, 285 disease states: normal, control, ... (283 more);, 126 cell types 490 cell lines 51 compound treatments and 89 other conditions.
Synonyms RIZ, MTB-ZF, HUMHOXY1, KMT8, RIZ2, RIZ1
Orthologs prdm2a (Danio rerio)   PRDM2 (Gallus gallus)   Prdm2 (Rattus norvegicus)   prdm2b (Danio rerio)   Blimp-1 (Drosophila melanogaster)   PRDM2 (Bos taurus)   NP_001123857.1 (Xenopus laevis)   Prdm2 (Mus musculus)   ENSCAFG00000024449 (Canis familiaris)   ENSCAFG00000016361 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2, SET_dom, RIZ_retinblastoma-bd_prot
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, intracellular, transcription, DNA-dependent, Golgi apparatus, metal ion binding, methyltransferase activity, nucleus, transferase activity, histone-lysine N-methyltransferase activity, zinc ion binding, sequence-specific DNA binding transcription factor activity, response to estradiol stimulus
UniProt Accession A8MW16, D6REL1, Q13029, D6RED5, D6RAA0, Q5THJ0, Q5THJ1, D6RJM6, A8MWY4, B1AJZ4
Search EB-eye ENSG00000116731
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-96, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
BT474
2
E-MEXP-440, E-MTAB-62
MDA468
2
E-MTAB-62, E-MEXP-440
Raji
2
E-MTAB-37, E-GEOD-96
484 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (59 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
3
E-AFMX-5, E-TABM-145, E-MTAB-25, E-GEOD-19069
1
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
dendritic cell
1
2
E-MEXP-2019, E-GEOD-360, E-GEOD-3982
120 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (76 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
prostate carcinoma
4
E-MEXP-2034, E-MTAB-62, E-MTAB-37, E-GEOD-7307
control
1
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-20295, E-GEOD-16728, E-GEOD-8121 ... (5 experiments)
colon carcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
chronic lymphocytic leukemia
1
2
E-GEOD-6691, E-MTAB-37, E-GEOD-2466
279 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (33 experiments)

Factor Value U/D Experiments
none
4
8
E-TABM-782, E-GEOD-412, E-MEXP-2345, E-GEOD-5824, E-MEXP-1958, ... (12 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
control
2
E-GEOD-3284, E-GEOD-5339
ponasterone A
1
E-GEOD-3113
4,5-dianilinophthalimide
2
1
E-GEOD-5258
nocodazole
1
E-GEOD-571
45 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (12 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-GEOD-18005, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-1956, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7540, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.438 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM